Covered recipient · General Payments record
YANELY MD PINEIRO PUEBLA
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$390.09
9 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $390.09 | 9 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Gilead Sciences, Inc. | $282.72 | 3 |
| Bayer Healthcare Pharmaceuticals Inc. | $42.84 | 2 |
| GlaxoSmithKline, LLC. | $18.19 | 1 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.08 | 1 |
| VIVUS LLC | $15.77 | 1 |
| Novartis Pharmaceuticals Corporation | $14.49 | 1 |
Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
YANELY MD PINEIRO PUEBLA
NPI 1750702189 · CMS profile ID 1311571
Allopathic & Osteopathic Physicians / Internal Medicine
PEMBROKE PINES, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1750702189?year=2023&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- YANELY MD PINEIRO PUEBLA, NPI 1750702189, CMS profile ID 1311571. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750702189?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). YANELY MD PINEIRO PUEBLA, NPI 1750702189, CMS profile ID 1311571. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750702189?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- YANELY MD PINEIRO PUEBLA, NPI 1750702189, CMS profile ID 1311571, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1750702189?year=2023&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
9 matching records · $390.09 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–9 of 9.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.08 | 12/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1057409301 | CMS |
| VIVUS LLC | $15.77 | 10/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1030253971 | CMS |
| GlaxoSmithKline, LLC. | $18.19 | 10/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1003249825 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $23.28 | 08/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1000351867 | CMS |
| Gilead Sciences, Inc. | $124.82 | 05/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025509315 | CMS |
| Gilead Sciences, Inc. | $115.20 | 03/30/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025517661 | CMS |
| Novartis Pharmaceuticals Corporation | $14.49 | 03/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 992761093 | CMS |
| Gilead Sciences, Inc. | $42.70 | 03/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025536809 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $19.56 | 01/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1000315295 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $3,200.00 | 1 |
| PY2025 | Principal investigator | $2,476,931.44 | 112 |
| PY2024 | Recipient | $3,200.00 | 1 |
| PY2024 | Principal investigator | $3,839,557.03 | 72 |
| PY2023 | Principal investigator | $3,154,711.62 | 75 |
| PY2022 | Principal investigator | $2,403,759.48 | 31 |
| PY2021 | Principal investigator | $506,403.80 | 19 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
73 records in PY2024
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $22,862.79 | 12/31/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression | No dispute reported | 06/30/2026 | 1136419048 |
| Principal investigator 1 | PFIZER INC. | $95,916.57 | 12/31/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130951375 |
| Recipient | PFIZER INC. | $3,200.00 | 12/30/2024 | Covered Recipient Physician | NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1130903847 |
| Principal investigator 1 | PFIZER INC. | $34,445.25 | 12/24/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130970702 |
| Principal investigator 1 | PFIZER INC. | $6,587.40 | 12/20/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130950770 |
| Principal investigator 1 | PFIZER INC. | $70,247.86 | 12/18/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130951386 |
| Principal investigator 1 | PFIZER INC. | $17.86 | 12/12/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130921038 |
| Principal investigator 1 | PFIZER INC. | $49,955.40 | 12/11/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130951381 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $485.00 | 12/10/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease (ADEPT-4) | No dispute reported | 06/30/2026 | 1155489358 |
| Principal investigator 1 | PFIZER INC. | $8.46 | 12/10/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130921306 |
| Principal investigator 1 | PFIZER INC. | $9,339.64 | 12/10/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130971100 |
| Principal investigator 1 | PFIZER INC. | $8,234.25 | 12/06/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130951210 |
| Principal investigator 1 | PFIZER INC. | $289,277.10 | 12/05/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130950775 |
| Principal investigator 1 | PFIZER INC. | $127,499.68 | 11/26/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130985262 |
| Principal investigator 1 | PFIZER INC. | $2,133.00 | 11/25/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130917623 |
| Principal investigator 1 | PFIZER INC. | $25.38 | 11/21/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130920930 |
| Principal investigator 1 | PFIZER INC. | $25.38 | 11/18/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130921310 |
| Principal investigator 1 | PFIZER INC. | $30.08 | 11/09/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130920922 |
| Principal investigator 1 | PFIZER INC. | $36,428.48 | 11/08/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130985473 |
| Principal investigator 1 | PFIZER INC. | $633.96 | 11/05/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130920926 |
| Principal investigator 1 | PFIZER INC. | $30.08 | 11/05/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130921034 |
| Principal investigator 1 | PFIZER INC. | $1,452.24 | 11/05/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130921302 |
| Principal investigator 1 | PFIZER INC. | $2,133.00 | 11/04/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130915992 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $17,121.00 | 10/15/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1128729418 |
| Principal investigator 1 | PFIZER INC. | $22,435.23 | 10/05/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130995883 |
| Principal investigator 1 | PFIZER INC. | $5,976.30 | 10/05/2024 | Non-covered Recipient Entity Palm Springs Community Health Center Corp | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1130995889 |
| Principal investigator 1 | PFIZER INC. | $113,603.12 | 09/25/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1131025132 |
| Principal investigator 1 | PFIZER INC. | $137,634.05 | 09/25/2024 | Non-covered Recipient Entity Palm Springs Community Health Center Corp | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1131026409 |
| Principal investigator 1 | PFIZER INC. | $175,022.31 | 09/11/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131025138 |
| Principal investigator 1 | PFIZER INC. | $85,914.51 | 09/04/2024 | Non-covered Recipient Entity Palm Springs Community Health Center Corp | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1131026404 |
| Principal investigator 1 | PFIZER INC. | $218,177.76 | 08/06/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131026668 |
| Principal investigator 1 | PFIZER INC. | $39,715.38 | 08/06/2024 | Non-covered Recipient Entity Palm Springs Community Health Center Corp | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1131026675 |
| Principal investigator 1 | PFIZER INC. | $97,905.51 | 08/02/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131026710 |
| Principal investigator 1 | PFIZER INC. | $22,875.32 | 08/02/2024 | Non-covered Recipient Entity Palm Springs Community Health Center Corp | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1131026716 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $74,351.01 | 07/19/2024 | Non-covered Recipient Entity Elias Research Associates Llc | Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimers Disease Dementia | No dispute reported | 06/30/2026 | 1123477148 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $1,054.30 | 07/18/2024 | Non-covered Recipient Entity ANGELS CLINICAL RESEARCH INSTITUTE INC | A Randomized, Double-Blind, Placebo-Controlled Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab | No dispute reported | 06/30/2026 | 1156048995 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $455,967.24 | 07/17/2024 | Non-covered Recipient Entity Elias Research Associates Llc | A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease Dementia | No dispute reported | 06/30/2026 | 1123477130 |
| Principal investigator 1 | PFIZER INC. | $106,350.57 | 07/10/2024 | Non-covered Recipient Entity Palm Springs Community Health Center Corp | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1131026615 |
| Principal investigator 1 | PFIZER INC. | $74,089.07 | 07/02/2024 | Non-covered Recipient Entity Palm Springs Community Health Center Corp | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1131026663 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $3,074.24 | 06/13/2024 | Non-covered Recipient Entity ANGELS CLINICAL RESEARCH INSTITUTE INC | A Randomized, Double-Blind, Placebo-Controlled Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab | No dispute reported | 06/30/2026 | 1156048803 |
| Principal investigator 1 | PFIZER INC. | $51,384.48 | 06/05/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131028007 |
| Principal investigator 1 | PFIZER INC. | $322.66 | 05/29/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131027659 |
| Principal investigator 1 | PFIZER INC. | $492,765.41 | 05/29/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131027833 |
| Principal investigator 1 | PFIZER INC. | $672.30 | 05/23/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1131025273 |
| Principal investigator 1 | PFIZER INC. | $637.60 | 05/23/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1131025365 |
| Principal investigator 1 | PFIZER INC. | $18,387.00 | 05/11/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131027861 |
| Principal investigator 1 | Amgen Inc. | $18,200.00 | 04/20/2024 | Non-covered Recipient Entity ANGELS CLINICAL RESEARCH INSTITUTE | ASCEND P3 AD Extension | No dispute reported | 06/30/2026 | 1096309027 |
| Principal investigator 1 | PFIZER INC. | $20,107.20 | 04/16/2024 | Non-covered Recipient Entity Angels Clinical Research Institute | A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 | No dispute reported | 06/30/2026 | 1130991861 |
| Principal investigator 1 | PFIZER INC. | $4,266.00 | 04/15/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1130916357 |
| Principal investigator 1 | PFIZER INC. | $2,650.00 | 04/10/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131027839 |
| Principal investigator 1 | PFIZER INC. | $86,880.46 | 04/05/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131027665 |
| Principal investigator 1 | PFIZER INC. | $1,350.10 | 04/04/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131025191 |
| Principal investigator 1 | PFIZER INC. | $975.40 | 03/30/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1131027183 |
| Principal investigator 1 | PFIZER INC. | $45,933.99 | 03/28/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131027366 |
| Principal investigator 1 | PFIZER INC. | $75,839.74 | 03/27/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131027147 |
| Principal investigator 1 | PFIZER INC. | $158,166.28 | 03/08/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131027212 |
| Principal investigator 1 | PFIZER INC. | $97,461.37 | 02/27/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131026639 |
| Principal investigator 1 | Amgen Inc. | $2,861.99 | 02/26/2024 | Non-covered Recipient Entity ANGELS CLINICAL RESEARCH INSTITUTE | ASTRO P3 AD Adolescent Mono | No dispute reported | 06/30/2026 | 1096309599 |
| Principal investigator 1 | PFIZER INC. | $7,654.50 | 02/24/2024 | Non-covered Recipient Entity Angels Clinical Research Institute | A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 | No dispute reported | 06/30/2026 | 1130991849 |
| Principal investigator 1 | PFIZER INC. | $1,250.00 | 02/21/2024 | Non-covered Recipient Entity Angels Clinical Research Institute | A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 | No dispute reported | 06/30/2026 | 1130991770 |
| Principal investigator 1 | PFIZER INC. | $81,619.44 | 02/14/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131026602 |
| Principal investigator 1 | PFIZER INC. | $97,195.44 | 02/14/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131027177 |
| Principal investigator 1 | PFIZER INC. | $141,321.11 | 02/13/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131027171 |
| Principal investigator 1 | PFIZER INC. | $15,125.00 | 02/08/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1131026644 |
| Principal investigator 1 | PFIZER INC. | $7.52 | 01/24/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131025196 |
| Principal investigator 1 | PFIZER INC. | $117.40 | 01/24/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131025202 |
| Principal investigator 1 | PFIZER INC. | $2,133.00 | 01/22/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1130916011 |
| Principal investigator 1 | PFIZER INC. | $2,000.00 | 01/17/2024 | Non-covered Recipient Entity Angels Clinical Research Institute | A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 | No dispute reported | 06/30/2026 | 1130991855 |
| Principal investigator 1 | PFIZER INC. | $469.60 | 01/17/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131025260 |
| Principal investigator 1 | PFIZER INC. | $176.10 | 01/16/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131025266 |
| Principal investigator 1 | PFIZER INC. | $11.28 | 01/16/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131025359 |
| Principal investigator 1 | PFIZER INC. | $30.08 | 01/16/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131025465 |
| Principal investigator 1 | PFIZER INC. | $2,548.80 | 01/09/2024 | Non-covered Recipient Entity Palm Springs Community Health Center | A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131027046 |